Open AccessArachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation
Author(s) -
David Fernández–Ramos,
Fernando LopitzOtsoa,
Laura delaCruzVillar,
Jon Bilbao,
Mario Pagano,
Laura Mosca,
Maider Bizkarguenaga,
Marina SerranoMaciá,
Mikel Azkargorta,
Marta IruarrizagaLejarreta,
Jesús Sot,
Darya Tsvirkun,
Sebastiaan Martijn Van Liempd,
Félix M. Goñi,
Cristina Alonso,
María Luz MartínezChantar,
Félix Elortza,
Liat Hayardeny,
Shelly C. Lu,
José M. Mato
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i34.5101
Subject(s) - nonalcoholic steatohepatitis , ampk , homeostasis , medicine , glucose homeostasis , pi3k/akt/mtor pathway , steatohepatitis , chemistry , endocrinology , bile acid , fatty liver , biochemistry , nonalcoholic fatty liver disease , diabetes mellitus , insulin resistance , protein kinase a , kinase , signal transduction , disease
Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis. In a phase IIb clinical trial in patients with nonalcoholic steatohepatitis (NASH), 52 wk of treatment with Aramchol reduced blood levels of glycated hemoglobin A1c, an indicator of glycemic control.